Search | Clinical Trials Finder

Conditions: Shigella, Diarrhea
Interventions: IVT Shigella-04, Placebo (0.9% saline); Biological
Lead sponsor: Inventprise Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Acute Myeloid Leukemia
Interventions: Dociparstat, Control; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Orange, California • Westwood, Kansas • Louisville, Kentucky + 11 more

Conditions: Blood Loss
Interventions: Intravenous Placebo, Intravenous Tranexamic Acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Intracerebral Hemorrhage (ICH)
Interventions: CN-105, Placebo; Drug
Lead sponsor: AegisCN LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Autism Spectrum Disorder
Interventions: Suramin Sodium; Drug
Lead sponsor: Paxmedica; Industry
Eligibility: 4 Years to 17 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Infertility
Interventions: Bravelle(follicle stimulating hormone), Saline ( placebo); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Abortion, Stillbirth, PTSD (Childbirth-Related), Grief (Traumatic Grief and Existential Grief)
Interventions: Dexmedetomidine (IV) 0.5 mcg/kg, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pain, Postoperative, Anterior Cruciate Ligament Injuries, Analgesics, Opioid
Interventions: IPACK, PLACEBO; Drug
Lead sponsor: Loyola University; Other
Eligibility: 16 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Sciatica
Interventions: epidural injection of etanercept, placebo (control procedure); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pain
Interventions: Hypertonic saline, Isotonic saline; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 20 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Nausea
Interventions: Ondansetron, Metoclopramide, Promethazine, Normal Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Autism, Severe Behavior Disorder
Interventions: placebo, glutathione, glutathione, vit C and NAC; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 5 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related
Interventions: patisiran (ALN-TTR02), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: La Mesa, California • Orange, California • Denver, Colorado + 9 more

Conditions: Hemorrhage/Blood Loss During Myomectomies, Fibroids
Interventions: Tranexamic Acid, Saline Solution; Drug · Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Parvovirus B19 Infection
Interventions: VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas

Conditions: Methamphetamine-dependence, Methamphetamine Abuse
Interventions: Placebo, IXT-m200; Drug
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Anaheim, California • Salt Lake City, Utah

Conditions: PTSD, Alcohol Use Disorder
Interventions: 40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Human Metapneumovirus Infection
Interventions: AZD0543, Placebo; Biological · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Alamitos, California • South Miami, Florida

Conditions: Postoperative Pain
Interventions: Acetaminophen or Placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Suicidal Ideation
Interventions: Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning; Drug · Other · Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Fort Hood, Texas • San Antonio, Texas

Conditions: Pain Management, Abortion, Second Trimester Abortion, Dilation and Evacuation
Interventions: Ketorolac, oral ibuprofen, Placebo, Lidocaine HCl 1%, Saline; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cystic Fibrosis
Interventions: Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Cleveland, Ohio

Search by objective public record fields.

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

Double Blind Trial in Children With Autism Spectrum Disorder

Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial

Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation

IPACK on Early Pain Scores After ACL Reconstruction

Efficacy of Epidural Etanercept in the Treatment of Sciatica

Effects of Anticipation of Pain Relief on Brain Mechanisms

Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

Use of Intravenous Tranexamic Acid During Myomectomy

B-19 Parvovirus Vaccine Study

Study of Antibody for Methamphetamine Outpatient Therapy

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

Study of Safety and PK of AZD0543 in Healthy Adults

Use of IV Acetaminophen in the Treatment of Post Operative Pain in Patients Undergoing Craniotomy and Spine Surgery

Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department

Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)